- Home
- DSP vs SMTI Comparison
DSP vs SMTI Comparison
Compare DSP & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- SMTI
- Stock Information
- Founded
- DSP 1999
- SMTI 1982
- Country
- DSP United States
- SMTI United States
- Employees
- DSP N/A
- SMTI 108
- Industry
- DSP EDP Services
- SMTI Medical/Dental Instruments
- Sector
- DSP Technology
- SMTI Health Care
- Exchange
- DSP Nasdaq
- SMTI Nasdaq
- Market Cap
- DSP 291.3M
- SMTI 297.2M
- IPO Year
- DSP 2021
- SMTI N/A
- Fundamental
- Price
- DSP $12.27
- SMTI $32.95
- Analyst Decision
- DSP Strong Buy
- SMTI Strong Buy
- Analyst Count
- DSP 7
- SMTI 2
- Target Price
- DSP $23.29
- SMTI $47.00
- AVG Volume (30 Days)
- DSP 653.0K
- SMTI 22.3K
- Earning Date
- DSP 03-03-2025
- SMTI 05-12-2025
- Dividend Yield
- DSP N/A
- SMTI N/A
- EPS Growth
- DSP N/A
- SMTI N/A
- EPS
- DSP 0.14
- SMTI N/A
- Revenue
- DSP $289,235,000.00
- SMTI $78,056,873.00
- Revenue This Year
- DSP $13.31
- SMTI $35.26
- Revenue Next Year
- DSP $16.25
- SMTI $20.79
- P/E Ratio
- DSP $87.00
- SMTI N/A
- Revenue Growth
- DSP 29.74
- SMTI 24.66
- 52 Week Low
- DSP $7.77
- SMTI $26.00
- 52 Week High
- DSP $26.33
- SMTI $39.08
- Technical
- Relative Strength Index (RSI)
- DSP 27.55
- SMTI 49.57
- Support Level
- DSP $11.62
- SMTI $30.81
- Resistance Level
- DSP $13.77
- SMTI $34.92
- Average True Range (ATR)
- DSP 1.15
- SMTI 1.31
- MACD
- DSP -0.37
- SMTI 0.23
- Stochastic Oscillator
- DSP 7.12
- SMTI 66.32
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.